Endotoxin and CD14 in the progression of biliary atresia

Table 1 Clinical characteristics of the child patients for this study

	Con-C	Early stage of BA		OPD	Late stage of BA		CC
	Plasma	Plasma	Liver	Plasma	Plasma	Liver	Plasma & Liver
Sample No	7	41	9	25	49	9	9
Age (months)	18 ± 24	2.4 ± 1.2	2 ± 1	24 ± 16	15 ± 10	15 ± 6	22 ± 14
Sex (M/F)	4/3	23/16	4/5	7/18	19/21	4/5	2/7
AST (U/l)	ND	200 ± 175^†	181 ± 130	ND	276 ± 241	246 ± 114	298 ± 228
T. Bil (mg/dl)	ND	9.0 ± 2.9^†	9.4 ± 3.0	ND	16 ± 1.0	18 ± 10	6.5 ± 6.0^†
D. Bil (mg/dl)	ND	6.3 ± 2.0^†	7.0 ± 2.3^†	ND	12 ± 7.5	13 ± 7.2	5.6 ± 4.0^†
sCD14 (μg/ml)	4.0 ± 0.8	4.7 ± 1.7^†	47 ± 14	4.2 ± 1.4^†	2.7 ± 1.5*^‡	49 ± 12	4.0 ± 2.0^†
Endotoxin (EU/ml)	2.0 ± 1.0	6.2 ± 5.0*^‡	17 ± 4.0	2.2 ± 5.0^†	6.7 ± 5.0*^‡	16 ± 7.0	6.5 ± 4.0*^‡

Con-C, control-children; Early stage of BA, Kasai's procedure for biliary atresia; OPD, Jaundice-free post-Kasai BA patients followed at the outpatient department; Late stage of BA, liver transplantation for biliary atresia; CC, choledochal cyst; AST, alanine aminotransferase; D. Bil, direct bilirubin; T. Bil, total bilirubin; ND, non detection; sCD14, souble CD14; y, years. Value are expressed as the mean ± SD. *P < 0.05 vs control; ^†P < 0.05 vs late stage of BA; ^‡P < 0.05 vs OPD.

ISSN: 1479-5876